Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Iurlo, Alessandra
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) Jan 2024 - Dec 2024: Approval for myelofibrosis Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis Feb 2024 - Feb 2024: Completion of P2b trial for JIA Feb 2024 - Feb 2024: Exclusivity expiry in US	Active, not recruiting	3	430	Europe, Canada, US, RoW	Pelabresib, Ruxolitinib, Placebo	Constellation Pharmaceuticals	Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	08/23	12/27
OPTKIMA, NCT02326311: Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response	Recruiting	3	502	Europe	imatinib, Glivec, nilotinib, Tasigna, dasatinib, Sprycell	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Leukemia, Chronic Myeloid	12/23	12/23
CarPAs, NCT04709731 / 2018-001334-18: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia	Not yet recruiting	2	50	Europe	Ponatinib 15mg QD, ICLUSIG, AP24534, Ponatinib 30mg QD	Associazione Italiana Pazienti Leucemia Mieloide Cronica	Chronic Myeloid Leukemia (CML)	10/24	04/25
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies	Active, not recruiting	1/2	122	Europe, US, RoW	Vodobatinib (K0706) capsules	Sun Pharma Advanced Research Company Limited	Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)	08/26	08/26
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation	Recruiting	N/A	3000	Europe, Canada		University of Milano Bicocca	Chronic Myeloid Leukemia	09/21	09/23
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19	Recruiting	N/A	552	Europe, US, RoW		Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net	Myeloproliferative Neoplasm, COVID	02/22	08/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors	Recruiting	N/A	148	Europe		Gruppo Italiano Malattie EMatologiche dell'Adulto	Chronic Myeloid Leukemia, Pregnancy	12/22	12/22
PHOENICS, NCT06119269: Ponatinib in CML Patients in Chronic Phase	Recruiting	N/A	100	Europe	Therapeutic drug monitoring, Molecular Response	University of Pisa	Chronic Myeloid Leukemia, Chronic Phase	01/24	12/24